TRxADE HEALTH, Inc. Stock

Equities

MEDS

US89846A4058

Internet Services

Market Closed - Nasdaq 16:30:00 2024-04-26 EDT 5-day change 1st Jan Change
6.31 USD +0.80% Intraday chart for TRxADE HEALTH, Inc. -1.87% +21.43%
Sales 2022 11.45M 15.65M Sales 2023 8.27M 11.31M Capitalization 6.48M 8.86M
Net income 2022 -3M -4.1M Net income 2023 -17M -23.24M EV / Sales 2022 0.37 x
Net Debt 2022 450K 615K Net Debt 2023 6.95M 9.5M EV / Sales 2023 1.62 x
P/E ratio 2022
-0.98 x
P/E ratio 2023
-0.22 x
Employees 8
Yield 2022 *
-
Yield 2023
-
Free-Float 75.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.80%
1 week-1.87%
Current month-38.38%
1 month-32.00%
3 months+43.47%
6 months+3.44%
Current year+21.43%
More quotes
1 week
5.82
Extreme 5.8201
7.08
1 month
5.82
Extreme 5.8201
10.74
Current year
3.69
Extreme 3.69
44.56
1 year
3.69
Extreme 3.69
44.56
3 years
3.69
Extreme 3.69
162.30
5 years
3.69
Extreme 3.69
174.00
10 years
3.69
Extreme 3.69
265.50
More quotes
Managers TitleAgeSince
Founder 49 05-07-14
Chief Executive Officer 53 05-07-14
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 53 05-07-14
Director/Board Member 62 16-08-23
Director/Board Member 66 22-09-29
More insiders
Date Price Change Volume
24-04-26 6.31 +0.80% 14,603
24-04-25 6.26 -2.95% 20,336
24-04-24 6.45 -0.77% 16,467
24-04-23 6.5 -2.40% 9,925
24-04-22 6.66 +3.58% 28,181

Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm

More quotes
TRxADE Health, Inc. provides a technology-enabled health services platform. The Company is focused on digitalizing the retail pharmacy and health services experience by optimizing drug procurement, the prescription journey, access to physicians in the patient’s home and patient engagement in the United States. The Company’s segments include Trxade, Inc., Integra Pharma Solutions, LLC (IPS) and Superlatus. Trxade, Inc. segment provides a web-based pharmaceutical marketplace platform-business to business (B2B) sales. IPS is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. The Superlatus segment holds Sapientia’s intellectual property for advanced food extrusion technology and The Urgent Company, which is a manufacturer of ice cream that is animal product-free, vegan, lactose-free, and made with plant-B2B sales. Its subsidiaries include Community Specialty Pharmacy, LLC, Alliance Pharma Solutions, LLC, Bonum Health, LLC and others.
More about the company